IR@PKUHSC  > 北京大学第三临床医学院  > 内分泌科
学科主题临床医学
The Effects of Pioglitazone on Biochemical Markers of Bone Turnover in the Patients with Type 2 Diabetes
Xiao, Wen-hua1; Wang, Yan-rong1; Hou, Wen-fang1; Xie, Chao1; Wang, Hai-ning1; Hong, Tian-pei1; Gao, Hong-wei1,2
刊名INTERNATIONAL JOURNAL OF ENDOCRINOLOGY
2013
DOI10.1155/2013/290734
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Endocrinology & Metabolism
研究领域[WOS]Endocrinology & Metabolism
关键词[WOS]MINERAL DENSITY ; OSTEOBLAST DIFFERENTIATION ; CONTROLLED-TRIAL ; ROSIGLITAZONE ; RISK ; DECREASES ; FRACTURE ; WOMEN ; THIAZOLIDINEDIONES ; ACTIVATION
英文摘要

Aim. To investigate whether pioglitazone had detrimental effects on biochemical markers of bone turnover in patients with type 2 diabetes (T2DM). Methods. Seventy patients with T2DM were included in this study. The patients remained on their previous antihyperglycemic therapies during the trial. Pioglitazone was then added on their regimen for 3 months. Results. After 3 months of treatment with pioglitazone, the levels of fasting blood glucose and HbA(1c) were significantly decreased (7.9 +/- 1.5 mmol/L versus 9.1 +/- 1.6 mmol/L and 7.1 +/- 1.0% versus 8.2 +/- 1.4%, resp., P < 0.01), compared with baseline in the overall patients. Serum concentrations of P1NP and BAP were significantly decreased from baseline (45.0 +/- 20.0 mu g/L versus 40.6 +/- 17.9 mu g/L and 13.23 +/- 4.7 mu g/L versus 12.3 +/- 5.0 mu g/L, resp., P < 0.01) in female group, but not in male group. The serum levels of OC and CTX were unchanged in both female and male subgroups. In addition, the levels of serum BAP and P1NP were significantly decreased after pioglitazone treatment in postmenopausal subgroup, comparing with baseline. Conclusion. Pioglitazone inhibits bone formation and does not seem to affect bone resorption. Postmenopausal female patients rather than premenopausal or male patients are particularly vulnerable to this side effect of pioglitazone.

语种英语
WOS记录号WOS:000321353800001
项目编号7123234 ; 2006CB503908 ; 2006AA02A112 ; 30771032 ; 30700879 ; 81070701 ; 81000315
资助机构Beijing Natural Science Foundation ; Chinese National 973 Program ; Chinese National 863 Program ; National Natural Science Foundation of China ; East China Pharmaceutical Company, Hangzhou, China
引用统计
被引频次:8[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/55644
专题北京大学第三临床医学院_内分泌科
作者单位1.Peking Univ, Dept Endocrinol, Hosp 3, Beijing 100191, Peoples R China
2.Peking Univ, Dept Endocrinol & Metab, Hosp 3, Beijing 100191, Peoples R China
推荐引用方式
GB/T 7714
Xiao, Wen-hua,Wang, Yan-rong,Hou, Wen-fang,et al. The Effects of Pioglitazone on Biochemical Markers of Bone Turnover in the Patients with Type 2 Diabetes[J]. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY,2013.
APA Xiao, Wen-hua.,Wang, Yan-rong.,Hou, Wen-fang.,Xie, Chao.,Wang, Hai-ning.,...&Gao, Hong-wei.(2013).The Effects of Pioglitazone on Biochemical Markers of Bone Turnover in the Patients with Type 2 Diabetes.INTERNATIONAL JOURNAL OF ENDOCRINOLOGY.
MLA Xiao, Wen-hua,et al."The Effects of Pioglitazone on Biochemical Markers of Bone Turnover in the Patients with Type 2 Diabetes".INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2013).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Xiao, Wen-hua]的文章
[Wang, Yan-rong]的文章
[Hou, Wen-fang]的文章
百度学术
百度学术中相似的文章
[Xiao, Wen-hua]的文章
[Wang, Yan-rong]的文章
[Hou, Wen-fang]的文章
必应学术
必应学术中相似的文章
[Xiao, Wen-hua]的文章
[Wang, Yan-rong]的文章
[Hou, Wen-fang]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。